| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Delays Mammary Tumor Formation Induced by Transgenic Expression of ErbB2/neu
Receptor Biology Section, Laboratory of Reproductive and Developmental Toxicology [S. C. H., W. P. B., C. H., L. K., K. S. K. [and Comparative Medicine Branch [J. C., P. M.], National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709, and Analytical Sciences, Inc., Durham, North Carolina 27713 [J. Z.]
Expression of the mouse mammary tumor virus (MMTV) neu/erbB2 transgene in mice induces mammary tumors. To examine the effect of removing estrogen receptor
(ER
) signaling on the ability of an MMTV-neu/erbB2 transgene to induce mammary tumors, the neu transgene was expressed in the ER
knockout (
ERKO) mouse, which lacks functional ER
. MMTV-neu females that lacked ER
still developed mammary tumors; however, tumor onset was significantly delayed. This study indicates that ER
is not required for mammary tumor induction by overexpression of neu/erbB2, but plays a role in the rate of tumor onset. The removal of ovarian steroid by ovariectomy in adults did not alter the onset rate. In contrast, prepubertal ovariectomy, which arrested mammary epithelial development, significantly delayed onset. In addition, manipulations that increase progesterone also accelerate the tumor onset, indicating the slower onset in the
ERKO is primarily attributable to the anovulatory phenotype resulting in lack of progesterone stimulation and a decreased abundance of target cells in the
ERKO mammary gland.
This article has been cited by other articles:
![]() |
S. N. Sundar, C. N. Marconett, V. B. Doan, J. A. Willoughby Sr, and G. L. Firestone Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells Carcinogenesis, December 1, 2008; 29(12): 2252 - 2258. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fereshteh, M. T. Tilli, S. E. Kim, J. Xu, B. W. O'Malley, A. Wellstein, P. A. Furth, and A. T. Riegel The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice Cancer Res., May 15, 2008; 68(10): 3697 - 3706. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Padilla-Banks, W. N. Jefferson, and R. R. Newbold Neonatal Exposure to the Phytoestrogen Genistein Alters Mammary Gland Growth and Developmental Programming of Hormone Receptor Levels Endocrinology, October 1, 2006; 147(10): 4871 - 4882. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Malewicz, Z. Wang, C. Jiang, J. Guo, M. P. Cleary, J. P. Grande, and J. Lu Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements Carcinogenesis, September 1, 2006; 27(9): 1739 - 1747. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rossini, C. Rumio, L. Sfondrini, E. Tagliabue, D. Morelli, R. Miceli, L. Mariani, M. Palazzo, S. Menard, and A. Balsari Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. Cancer Res., June 15, 2006; 66(12): 6219 - 6224. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Medina, F. S. Kittrell, J. Hill, A. Shepard, G. Thordarson, and P. Brown Tamoxifen Inhibition of Estrogen Receptor-{alpha}-Negative Mouse Mammary Tumorigenesis Cancer Res., April 15, 2005; 65(8): 3493 - 3496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Frech, E. D. Halama, M. T. Tilli, B. Singh, E. J. Gunther, L. A. Chodosh, J. A. Flaws, and P. A. Furth Deregulated Estrogen Receptor {alpha} Expression in Mammary Epithelial Cells of Transgenic Mice Results in the Development of Ductal Carcinoma In situ Cancer Res., February 1, 2005; 65(3): 681 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Zinser and J. Welsh Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Q. Kuang, L. Liao, H. Zhang, A. V. Lee, B. W. O'Malley, and J. Xu AIB1/SRC-3 Deficiency Affects Insulin-Like Growth Factor I Signaling Pathway and Suppresses v-Ha-ras-induced Breast Cancer Initiation and Progression in Mice Cancer Res., March 1, 2004; 64(5): 1875 - 1885. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yeh, Y.-C. Hu, P.-H. Wang, C. Xie, Q. Xu, M.-Y. Tsai, Z. Dong, R.-S. Wang, T.-H. Lee, and C. Chang Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor J. Exp. Med., December 15, 2003; 198(12): 1899 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Medina, F. S. Kittrell, A. Shepard, A. Contreras, J. M. Rosen, and J. Lydon Hormone Dependence in Premalignant Mammary Progression Cancer Res., March 1, 2003; 63(5): 1067 - 1072. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Levin Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor Mol. Endocrinol., March 1, 2003; 17(3): 309 - 317. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |